Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Southern Blot Analysis – V 2.0

Posted on By


Biosimilars: SOP for Southern Blot Analysis – V 2.0


Standard Operating Procedure for Southern Blot Analysis in Biosimilar Cell Lines

Department Biosimilars
SOP No. SOP/BS/018/2025
Supersedes SOP/BS/018/2022
Page No. Page 1 of 14
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the method for performing Southern blot analysis for confirming transgene integration, determining gene copy number, and detecting rearrangements in genetically modified biosimilar-producing cell lines.

2. Scope

This SOP applies to the Molecular Biology and Cell Line Development teams responsible for genetic characterization and verification of recombinant clones used in biosimilar production.

3. Responsibilities

  • Molecular Biologist: Carries out the complete Southern blot procedure and interprets results.
  • Lab Assistant: Prepares reagents, assists with electrophoresis and blotting steps.
  • QA Representative: Verifies documentation and ensures traceability of results.
See also  Biosimilars: SOP for Adaptation of Cells to Serum-Free Media - V 2.0

4. Accountability

The Head of Molecular Biology is accountable for ensuring the accurate execution and compliance of Southern blot assays as part of clone characterization in biosimilar programs.

5. Procedure

5.1 Genomic DNA Preparation

  1. Isolate high molecular weight DNA from 1 × 107 cells using phenol-chloroform extraction.
  2. Check DNA quality using agarose gel electrophoresis and spectrophotometry.

5.2 Restriction Enzyme Digestion

  1. Digest 10 µg genomic DNA with restriction enzymes that cut outside the transgene insertion site.
  2. Use at least 1 unit of enzyme per µg DNA and incubate overnight at 37°C.

5.3 Gel Electrophoresis and Denaturation

  1. Run digested DNA on 0.8% agarose gel at 40V overnight.
  2. Soak gel in 0.25M HCl for 10 minutes to depurinate.
  3. Denature in 1.5M NaCl, 0.5M NaOH for 30 minutes, followed by neutralization in 1.5M NaCl, 0.5M Tris-HCl pH 7.5.

5.4 Capillary Blotting

  1. Transfer DNA onto a nylon membrane overnight via capillary transfer in 20X SSC buffer.
  2. Cross-link DNA to membrane using UV crosslinker or baking at 80°C for 2 hours.
See also  Biosimilars: SOP for mRNA Transcript Analysis (RT-PCR) - V 2.0

5.5 Probe Preparation and Hybridization

  1. Label the DNA probe (complementary to transgene) using radioactive or digoxigenin-based labeling.
  2. Prehybridize membrane in hybridization buffer for 1 hour at 42°C.
  3. Add labeled probe and hybridize overnight at 42–68°C depending on probe type.

5.6 Washing and Detection

  1. Wash membrane with decreasing stringency buffers (e.g., 2X SSC, 0.1X SSC).
  2. Detect signals using X-ray film (radioactive) or chemiluminescent substrate (DIG).
  3. Interpret number and intensity of bands to determine gene copy number and integration pattern.
  4. Document in Southern Blot Result Log (Annexure-1).

6. Abbreviations

  • SSC: Saline-Sodium Citrate Buffer
  • DIG: Digoxigenin
  • UV: Ultraviolet
  • X-ray: Radiographic Detection Method

7. Documents

  1. Southern Blot Result Log (Annexure-1)
  2. Probe Synthesis and Labeling Record (Annexure-2)

See also  Biosimilars: SOP for Vector Design and Cloning - V 2.0

8. References

  • WHO TRS 999 – Genetic Stability Testing of Cell Substrates
  • ICH Q5B – Quality of Biotechnological Products: Analysis of Expression Constructs
  • CDSCO Guidelines on Recombinant Cell Line Characterization

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Southern Blot Result Log

Date Clone ID Restriction Enzyme Band Count Band Size(s) Remarks Operator
03/05/2025 CL-BS-018 EcoRI 3 3.2kb, 2.8kb, 1.5kb Multiple integrations Rajesh Kumar

Annexure-2: Probe Synthesis and Labeling Record

Probe Name Target Gene Labeling Method Lot No. Prepared By Date
pEPO-3 rhEPO DIG DG2025 Sunita Reddy 02/05/2025

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Updated hybridization buffer and added DIG detection method Annual SOP update
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: SOP for Documentation of Raw Material Issuance in ERP System – V 2.0
Next Post: BA-BE Studies: SOP for Plasma Separation and Aliquoting – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version